HER2-Negative Breast Cancer Completed Phase 1 Trials for Irinotecan (DB00762)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0072181 (HER2-Negative Breast Cancer) | Completed | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | Treatment |